In Cancer Immunotherapy Legal Battle, It's Now Juno v. Novartis
This article was originally published in Start Up
In one of biopharma's hottest fields, a patent dispute between the University of Pennsylvania and St. Jude Children's Research Hospital could become an industry fight between a rising biotech star and a pharma heavyweight.
You may also be interested in...
Novartis’ deal with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor technologies developed in the lab of Penn’s Carl June comes at an opportune time. The Big Pharma is fighting to preserve its number two ranking in oncology and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca in neurodegenerative disease is winding down.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.